2018 Arterial Thrombosis Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Arterial Thrombosis Market
Thrombosis refers to a serious heart condition in which arteries or veins are blocked because of blood clot in the blood vessel. Based on the location of clot, it is classified as Venous and Arterial Thromboembolism.
Venous Thromboembolism (VTE) is classified further as deep vein thrombosis (DVT) and pulmonary embolism (PE). In DVT, the clot in veins lies deep inside muscled while in PE, the clot is nearby lungs.
Arterial Thromboembolism refers to a clot in the arteries carrying blood to different body parts. If arteries towards brain are affected, it can cause stroke and if coronary arteries are affected, it is acute coronary syndrome.
An estimated 10 million population is affected by Thromobisis worldwide every year.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Arterial Thrombosis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Arterial Thrombosis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Arterial Thrombosis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Venous Thromboembolism (VTE) is classified further as deep vein thrombosis (DVT) and pulmonary embolism (PE). In DVT, the clot in veins lies deep inside muscled while in PE, the clot is nearby lungs.
Arterial Thromboembolism refers to a clot in the arteries carrying blood to different body parts. If arteries towards brain are affected, it can cause stroke and if coronary arteries are affected, it is acute coronary syndrome.
An estimated 10 million population is affected by Thromobisis worldwide every year.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Arterial Thrombosis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Arterial Thrombosis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Arterial Thrombosis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 ARTERIAL THROMBOSIS PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Arterial Thrombosis Pipeline Snapshot
2.3 Arterial Thrombosis Pipeline by Phase
2.4 Arterial Thrombosis Pipeline by Company
2.5 Arterial Thrombosis Pipeline by Mechanism of Action
3 ARTERIAL THROMBOSIS- COMPANY WISE PIPELINE ANALYSIS
Astellas Pharma Inc
Bayer AG
Bristol-Myers Squibb Company
Sanofi SA
4 ARTERIAL THROMBOSIS R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN ARTERIAL THROMBOSIS PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 ARTERIAL THROMBOSIS PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Arterial Thrombosis Pipeline Snapshot
2.3 Arterial Thrombosis Pipeline by Phase
2.4 Arterial Thrombosis Pipeline by Company
2.5 Arterial Thrombosis Pipeline by Mechanism of Action
3 ARTERIAL THROMBOSIS- COMPANY WISE PIPELINE ANALYSIS
Astellas Pharma Inc
Bayer AG
Bristol-Myers Squibb Company
Sanofi SA
4 ARTERIAL THROMBOSIS R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN ARTERIAL THROMBOSIS PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Arterial Thrombosis Pipeline by Phase, H2- 2018
Figure 2: Arterial Thrombosis Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Arterial Thrombosis Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
Figure 1: Arterial Thrombosis Pipeline by Phase, H2- 2018
Figure 2: Arterial Thrombosis Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Arterial Thrombosis Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
LIST OF TABLES
Arterial Thrombosis Pipeline by Phase, H2- 2018
Arterial Thrombosis Pipeline by Companies, H2- 2018
Arterial Thrombosis Pipeline by Mechanism of Action, H2- 2018
Table 1: Astellas Pharma Inc Arterial Thrombosis Pipeline Drugs, H2- 2018
Table 2: Bayer AG Arterial Thrombosis Pipeline Drugs, H2- 2018
Table 3: Bristol-Myers Squibb Company Arterial Thrombosis Pipeline Drugs, H2- 2018
Table 4: Sanofi SA Arterial Thrombosis Pipeline Drugs, H2- 2018
Arterial Thrombosis Pipeline by Phase, H2- 2018
Arterial Thrombosis Pipeline by Companies, H2- 2018
Arterial Thrombosis Pipeline by Mechanism of Action, H2- 2018
Table 1: Astellas Pharma Inc Arterial Thrombosis Pipeline Drugs, H2- 2018
Table 2: Bayer AG Arterial Thrombosis Pipeline Drugs, H2- 2018
Table 3: Bristol-Myers Squibb Company Arterial Thrombosis Pipeline Drugs, H2- 2018
Table 4: Sanofi SA Arterial Thrombosis Pipeline Drugs, H2- 2018
